secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-095687
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q2 revenue down 14% to $25.2M, net income up to $4.5M; receives NMPA approval for avatrombopag
--------------------------------------------------------------------------------

- Q2 revenue $25.2M (-14% YoY) on normalized ETUARY sales; net income $4.5M vs $3.8M YoY.
- H1 revenue $52.4M (-3.5% YoY); net income $14.5M vs $8.0M YoY, driven by lower costs.
- Received NMPA approval for avatrombopag for CLD thrombocytopenia (July 2024); expanded rare disease portfolio.
- IND approved for F230 in PAH; Phase 3 F351 CHB data expected early 2025; U.S. IND for F351 in MASH by end 2024.
- Appointed David M. Epstein to Board; cash and investments ~$54M, sufficient for 12+ months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024095687/0000950170-24-095687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024095687/gyre-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer